Vor Biopharma Inc. (VOR) NASDAQ
13.68
-0.895(-6.14%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vor Biopharma Inc.
Address
100 Cambridgepark Drive
Cambridge, MA 02140
United States of America (the)
Phone
617 655 6580
Website
Sector
Healthcare
Industry
Biotechnology
Employees
159
First IPO Date
February 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Jean-Paul Kress | Chairman, President & CEO | 1.01M | 1965 |
| Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | 603,814 | 1965 |
| Jeremy Sokolove | Chief Medical Officer | 695,160 | 1974 |
| Robert Ang MBBS | Strategic Advisor | 2M | 1975 |
| Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | 0 | 1971 |
| Carol Lincoln | Head of Human Resources | 0 | N/A |
| Navid Z. Khan | Chief Medical Affairs Officer | 0 | N/A |
| Adi Osovsky | General Counsel | 0 | N/A |
| Dallan Murray | Chief Commercial Officer | 0 | 1970 |
| Qing Zuraw | Executive Officer | 0 | N/A |
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
